NASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free APLS Stock Alerts $42.00 -0.56 (-1.32%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$41.73▼$42.9550-Day Range$39.25▼$56.8452-Week Range$19.83▼$92.61Volume676,317 shsAverage Volume1.48 million shsMarket Capitalization$5.10 billionP/E RatioN/ADividend YieldN/APrice Target$74.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Apellis Pharmaceuticals alerts: Email Address Apellis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside77.1% Upside$74.38 Price TargetShort InterestBearish10.81% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment1.42Based on 6 Articles This WeekInsider TradingSelling Shares$8.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to $0.79 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.34 out of 5 starsMedical Sector120th out of 915 stocksPharmaceutical Preparations Industry48th out of 430 stocks 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.81% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 4.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 3.0 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Apellis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 12 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,962,496.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.15) to $0.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 25.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Apellis Pharmaceuticals Stock (NASDAQ:APLS)Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesJune 7, 2024 | americanbankingnews.comBrokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $74.38June 5, 2024 | globenewswire.comApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 28, 2024 | finance.yahoo.comThe Future of Cannabidiol (CBD) Pain Treatments, 2024: Commercial and Clinical Assessment with Analysis of Pipeline Development ActivitiesMay 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)May 28, 2024 | markets.businessinsider.comExpert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 AnalystsMay 24, 2024 | globenewswire.comPositive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressMay 14, 2024 | finance.yahoo.comApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetMay 13, 2024 | seekingalpha.comApellis Pharmaceuticals Strives For Recovery Despite Syfovre SetbacksMay 10, 2024 | markets.businessinsider.comStrong Performance and Growth Potential Affirm Buy Rating for Apellis PharmaceuticalsMay 8, 2024 | markets.businessinsider.comApellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive PressuresMay 8, 2024 | msn.comApellis stock sell-off over Syfovre sales "overdone," says CitiMay 8, 2024 | markets.businessinsider.comIn-Depth Examination Of 14 Analyst Recommendations For Apellis PharmaceuticalsMay 8, 2024 | finance.yahoo.comApellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 7, 2024 | finanznachrichten.deApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | msn.comAPLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | msn.comApellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04MMay 7, 2024 | globenewswire.comApellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comApellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceMay 1, 2024 | globenewswire.comApellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingApril 30, 2024 | investing.comApellis Pharmaceuticals stock falls following Mizuho comments, price target cutApril 30, 2024 | benzinga.comA Closer Look at Apellis Pharmaceuticals's Options Market DynamicsApril 26, 2024 | globenewswire.comApellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)April 23, 2024 | globenewswire.comApellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsApril 18, 2024 | benzinga.comBehind the Scenes of Apellis Pharmaceuticals's Latest Options TrendsSee More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/14/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees702Year Founded2009Price Target and Rating Average Stock Price Target$74.38 High Stock Price Target$106.00 Low Stock Price Target$46.00 Potential Upside/Downside+77.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-528,630,000.00 Net Margins-79.67% Pretax Margin-79.24% Return on Equity-160.77% Return on Assets-49.79% Debt Debt-to-Equity Ratio0.35 Current Ratio3.77 Quick Ratio3.02 Sales & Book Value Annual Sales$396.59 million Price / Sales12.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book25.61Miscellaneous Outstanding Shares121,370,000Free Float113,113,000Market Cap$5.10 billion OptionableOptionable Beta0.95 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Comp: $1.44MMr. Mark Jeffrey Delong (Age 47)Chief Business & Strategy Officer Dr. Philip Ferrone M.D.Chief Medical Retina AdvisorKey CompetitorsEidos TherapeuticsNASDAQ:EIDXRa PharmaceuticalsNASDAQ:RARXALX OncologyNASDAQ:ALXOOmerosNASDAQ:OMERRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsArtal Group S.A.Sold 106,064 shares on 5/17/2024Ownership: 1.084%Ikarian Capital LLCBought 100,000 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCSold 1,100 shares on 5/17/2024Ownership: 0.000%Comerica BankBought 6,804 shares on 5/17/2024Ownership: 0.007%Tidal Investments LLCBought 4,527 shares on 5/17/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions APLS Stock Analysis - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price target for 2024? 16 Wall Street research analysts have issued 12 month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $46.00 to $106.00. On average, they expect the company's share price to reach $74.38 in the next year. This suggests a possible upside of 77.1% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2024? Apellis Pharmaceuticals' stock was trading at $59.86 at the beginning of 2024. Since then, APLS stock has decreased by 29.8% and is now trading at $42.00. View the best growth stocks for 2024 here. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.54) EPS for the quarter, hitting analysts' consensus estimates of ($0.54). The company had revenue of $172.33 million for the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative trailing twelve-month return on equity of 160.77%. The business's revenue for the quarter was up 284.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.56) earnings per share. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), Jacob Forward ETF (JFWD), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.84%), Jennison Associates LLC (2.67%), Price T Rowe Associates Inc. MD (2.03%), Assenagon Asset Management S.A. (1.68%), Artal Group S.A. (1.08%) and Iron Triangle Partners LP (0.45%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More This page (NASDAQ:APLS) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.